Clinical Research Details

Descriptive Information
A Collaborative Pediatric Retinoblastoma Program to improve access to specialized care

Raya Saab


Clinical Research - Outcomes Research and Health Services Research  

  • Miguel Abboud
  • Samar Muwakkit
  • Hassan El-Solh
Zeina Merabi
Conditions and Keywords
National collaboration for optimal clinical care of pediatric patients with malignant orbital tumors
Retinoblastoma,Pediatrics,Global Oncology
Study Design
Health Services Research
N/A: Not Applicable
Eligibility and IRB
Min: 0
Max: 18

 In Lebanon, a small country in the Middle East, there are a total of less than 20 pediatric oncologists, who work at multiple hospitals across the country. In 2012, within a program development initiative sponsored by St Jude Children’s Research Hospital, the majority of pediatric oncologists agreed to establish a cooperative group, within which to initiate collaborative treatment programs for childhood tumors. The hypothesis is that centralized diagnosis and staging and coordinated treatment would result in better patient outcomes. Outcome would also be improved by enhanced access to technically specialized and expensive procedures by eliminating financial barriers, and ensuring expert care.

To establish feasibility, the newly formed group (Lebanese Children’s Oncology Group, LCOG) focused on pediatric Orbital tumors; The most common malignant is Retinoblstoma.


Patients aged below 18 years diagnosed with Retinoblastoma that were enrolled on the collaborative Retinoblastoma program and in the period of July 1 2012 to June 30 2015

Retrospective chart review will be applied to all children diagnosed with Retinoblastoma that were enrolled on the Collaborative Retinoblastoma program between July 1, 2012 and June 30, 2015

Collected data include chemotherapy details, associated delays and toxicities, local control modality (surgery, radiation), acute and chronic complications, and patient outcome

1- Patients younger than the age of 18 years of age

2-Diagnosed with Retinoblastoma

3-Enrolled on the collaborative bone tumor program

Patients who do not fit the inclusion criteria are not eligible.